MENSTRUAL CRAMPS TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

Menstrual Cramps Treatment Market is estimated to be valued at USD 743.4 Mn in 2026 and is expected to reach USD 1,018.4 Mn in 2033, exhibiting a compound annual growth rate (CAGR) of 4.6% from 2026 to 2033.

Increasing product launching activity of market players expected to increase the market over the forecast period. For instance, on March 31, 2022, Bayer (Bayer AG is a German multinational pharmaceutical and biotechnology company) launches VISANNE is indicated for the management of pelvic pain associated with endometriosis.

Analysts’ Views on Global Menstrual Cramps Treatment market:

Global menstrual cramps treatment market is expected to witness growth, deu to manufacturers such as , Hope Medicine (Nanjing) Co., Ltd, Organon & Co. are focusing on increasing the research and developement activities for the development of novel treatments for menstrual cramps. For Instance, the Hope Medicine (Nanjing) Co., Ltd is developing a drug HMI-115 for the condition  Endometriosis which is under the clinical trial Phase 2. Study starts on November 1, 2021.

Figure 1. Global menstrual cramps treatment market  (%), by Drug Class, 2026

Global Menstrual Cramps  Treatment Market - Drivers

Increasing Product Approvals for Menstrual Cramps Treatment Market

Increasing product approvals for menstrual cramps treatment by regulatory bodies is expected to drive the market growth over the forecast period. For instance, on May 26, 2021, Pfizer Inc., received the U.S. Food and Drug Administration approval for MYFEMBREE. MYFEMBREE (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) is once-daily treatment for heavy menstrual bleeding associated with painful periods. It is approved for treatment of Menstrual cramps and duration is up to 24 months. MYFEMBREE Support Program provides services such as insurance benefits checks, co-pay support for commercially insured patients, and patient assistance for qualified uninsured patients.

Global Menstrual Cramps Treatment Market- Regional Analysis

Among region, North America dominated the market growth in 2026, owing to presence of key players such as Pfizer Inc., Abbott, among others in region.

Europe region is expected to be the second largest market over the forecast period, towing to rising adoption of strategies such as awareness programmes by Europian Union in the region for the development of applications that aim to reduce clinical symptoms of health conditions. For instance, on 27 May, 2022, according to World Health Organisation Europe (WHO/Europe), education and provisions is provided at school for management of menstrual hygiene. On Menstrual Hygiene Day, 28 May, WHO/Europe calls on countries to redouble efforts to strengthen menstrual hygiene measures in schools, in order to prevent adverse health consequences. WHO/Europe is working with countries to assess the problem, support strengthening capacity, accelerate water and sanitation improvements in schools, and promote policies to ensure safe, hygienic, and dignified menstruation.

Figure 2. Global menstrual cramps treatment market  (%), by Region, 2026

Pharmaceutical companies faced problems regarding transportation of drug products. Link between regional warehouses is not smooth for transportation of raw materials. The shortage of raw materials and components affected the supply chain of the global menstrual cramps treatment market. Due to the severe shortage of medical equipements at the front line, only patients diagnosed with serious conditions can be hospitalized.

Global Menstrual Cramps Treatment Market- Segmentation :

Global Menstrual Cramps Treatment market is segmented into by drug class, type, route of administration, dosage form, distribution channel, and region.

On the basis of drug class, the market is segmented into analgesics, anticholinergics, non-steroidal anti-inflammatory drugs (NSAIDs), haematinics, and others (progestins and among others).  Out of which, non-steroidal anti-inflammatory drugs (NSAIDs) segment dominated the market. According to article published in International Journal of Environmental Research and Public Health, 13 February 2020,  NSAIDs  used as a firstline pain relievent in menstrual cramps. NSAIDs act by inhibiting cyclo-oxygenase (COX), which is the enzyme responsible for the synthesis of prostaglandins. It has been demonstrated that a reduced production of prostaglandins decreases the strength of uterine contractions, thus relieving women’s discomfort.

On the basis of type, global menstrual cramps treatment market  is segmented into primary dysmenorrhea and secondary dysmenorrhea. According to article published by BMC Women's Health journal on 06 January 2020, the prevalence of primary dysmenorrhea varies from between 16 to 92%.

On the basis of route of administration, the market has been divided into oral, injectable, topical, and others (intrauterine, among others). Oral segment is expected to dominate the market over the forecast period, due to increasing approvals of oral tablets by regulatory bodies.

On the basis of dosage form, the market has been divided into tablet, capsules, suspension, and others (transdermal patch, among others). Tablet segment is expected to dominate the market over the foecast period, as drugs are present in tablet form are under the clinical trials.

On the basis of distribution channel, the market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies. For instance, on 15 February 2022, Government of India are focusing on running special awareness programs and publicity of important activities like hygiene, management related to Pharmaceuticals in “Jan Aushadhi Kendra” for the menstrual cramps treatment through healthcare facilities, therefore the, hospital pharmacies segment is expected to dominate the market over the forecast period.

Global Menstrual Cramps Treatment market Cross Sectional Analysis:

In the drug class segment, the NSAID’s are helding dominant position in primary dismenorrhea due to increasing prevalence of endometriosis and dysmenorrhea and the availability of Tablets for the treatment of dysmenoeehea. For instance, according to article published in Korean Journal of Family Medicine, on March 17, 2022, shows that the NSAID’s tablets are firstline therapy for primary dysmenorrhea. NSAID’s inhibit the production of prostaglandins, that are directly correlated to menstrual pain and its associated systemic symptoms.

Global Menstrual Cramps Treatment Market: Key Developments

On December 28, 2020, Myovant Sciences Ltd, a subsidiary of Sumitovant Biopharma Ltd, a biopharmaceutical company, and Pfizer. Inc., a U.S.-based multinational pharmaceutical and biotechnology corporation, collaborated for development and commercialization of Relugolix for treatment of heavy menstrual bleeding associated with uterine fibroids and endometriosis.

Global Menstrual Cramps Treatment Market: Restraint

Availability of alternative treatment:

Availability of alternative treatment for the management of menstrual cramps hampering the market of menstrual cramps treatment. For Instance, on 3 Mar 2023,  iPulse Medical Ltd. Offering medical device for the treatment of menstrual cramps.  Livias Portable device,  a drug free solution for menstrual pain is expected to hamper the market growth. Using proprietary SmartWave technology based on the gate control theory, Livia transmits special micro-pulses to keep the nerves “busy” and block the signals that cause period pain. Retrain can be overcome by increasing medical reimbursement on drugs which are indicated for the treatment of menstrual cramps.

Global Menstrual Cramps  Treatment Market:  Key Players

Major players operating in the global menstrual cramps  treatment market include Pfizer Inc.,  Ingelheim International GmbH.,  Bayer AG,  Abbott.,  Cipla Inc,  Teva Pharmaceutical Industries Ltd.,  Sanofi,  Johnson & Johnson Services, Inc.,  Dr. Reddy’s Laboratories Ltd,  Almatica Pharma LLC., F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Eisen Pharmaceutical Co.(Pvt.) Ltd., Emcure Pharmaceuticals, AbbVie., and Sparsha Pharma International Pvt Ltd, Hope Medicine (Nanjing) Co., Ltd.

*Definition: Menstruation or period is normal vaginal bleeding that happens as part of a woman's monthly cycle. Many women have painful periods, also known as as dysmenorrhea. The pain is known as menstrual cramps that is  a throbbing, cramping pain in lower abdomen. Symptoms occured such as lower back pain, nausea, diarrhea and headaches. On the basis of its types,  it is divided into primary and secondary dysmenorrhea.  Primary dysmenorrhea is the most common kind of period pain which is caused by many prostaglandins made by uterus.